Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
LQDA Stock Forecast 2026-2027
$37.58
Current Price
$3.27B
Market Cap
Buy 8
Hold 0
Sell 1
Wall St Analyst Ratings
Distance to LQDA Price Targets
+78.3%
To High Target of $67.00
+43.7%
To Median Target of $54.00
-49.4%
To Low Target of $19.00
LQDA Price Momentum
+4.3%
1 Week Change
-1.6%
1 Month Change
+167.9%
1 Year Change
+9.0%
Year-to-Date Change
-19.5%
From 52W High of $46.67
+233.7%
From 52W Low of $11.26
📊 TOP ANALYST CALLS
Did LQDA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if iShares Bond ETF is one of their latest high-conviction picks.
Latest LQDA Stock Price Targets & Analyst Predictions
Based on our analysis of 15 Wall Street analysts, LQDA has a bullish consensus with a median price target of $54.00 (ranging from $19.00 to $67.00). The overall analyst rating is Strong Buy (8.9/10). Currently trading at $37.58, the median forecast implies a 43.7% upside. This outlook is supported by 8 Buy, 0 Hold, and 1 Sell ratings.
Conversely, the most conservative target is provided by Serge Belanger at Needham, suggesting a 49.4% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LQDA Analyst Ratings
8
Buy
0
Hold
1
Sell
LQDA Price Target Range
Low
$19.00
Average
$54.00
High
$67.00
Current: $37.58
Latest LQDA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LQDA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 6, 2026 | HC Wainwright & Co. | Andrew S. Fein | Buy | Maintains | $55.00 |
| Mar 6, 2026 | Wells Fargo | Benjamin Burnett | Overweight | Maintains | $44.00 |
| Mar 5, 2026 | Needham | Serge Belanger | Buy | Maintains | $54.00 |
| Mar 5, 2026 | BTIG | Julian Harrison | Buy | Maintains | $50.00 |
| Feb 25, 2026 | Needham | Serge Belanger | Buy | Reiterates | $52.00 |
| Jan 13, 2026 | Jefferies | Amy Li | Buy | Maintains | $55.00 |
| Jan 13, 2026 | BTIG | Julian Harrison | Buy | Reiterates | $49.00 |
| Dec 26, 2025 | BTIG | Julian Harrison | Buy | Reiterates | $49.00 |
| Nov 4, 2025 | HC Wainwright & Co. | Andrew S. Fein | Buy | Maintains | $50.00 |
| Nov 4, 2025 | BTIG | Julian Harrison | Buy | Reiterates | $49.00 |
| Nov 4, 2025 | Needham | Serge Belanger | Buy | Maintains | $52.00 |
| Oct 6, 2025 | HC Wainwright & Co. | Andrew S. Fein | Buy | Reiterates | $35.00 |
| Aug 15, 2025 | Jefferies | Amy Li | Buy | Assumes | $43.00 |
| Aug 13, 2025 | Raymond James | Ryan Deschner | Strong Buy | Maintains | $41.00 |
| Aug 13, 2025 | Wells Fargo | Tiago Fauth | Overweight | Maintains | $31.00 |
| Aug 12, 2025 | Needham | Serge Belanger | Buy | Maintains | $36.00 |
| Jun 12, 2025 | Wells Fargo | Tiago Fauth | Overweight | Maintains | $25.00 |
| Jun 11, 2025 | B of A Securities | Jason Gerberry | Buy | Maintains | $23.00 |
| Jun 2, 2025 | Needham | Serge Belanger | Buy | Maintains | $32.00 |
| May 28, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $35.00 |
Liquidia Corporation (LQDA) Competitors
The following stocks are similar to iShares Bond ETF based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
LQDA
iShares Corp Bond ETF
mkt cap
3.14B
Liquidia Corporation (LQDA) Financial Data
Liquidia Corporation has a market capitalization of $3.27B with a P/E ratio of -22.7x. The company generates $158.32M in trailing twelve-month revenue with a -43.5% profit margin.
Revenue growth is +3,054.6% quarter-over-quarter, while maintaining an operating margin of +21.5% and return on equity of -111.1%.
Valuation Metrics
Market Cap
$3.27B
Enterprise Value
$3.40B
P/E Ratio
-22.7x
PEG Ratio
0.3x
Price/Sales
21.2x
Growth & Margins
Revenue Growth (YoY)
+3,054.6%
Gross Margin
+94.2%
Operating Margin
+21.5%
Net Margin
-43.5%
EPS Growth
+1,121.7%
Financial Health
Cash/Price Ratio
+5.8%
Current Ratio
2.0x
Debt/Equity
442.3x
ROE
-111.1%
ROA
-11.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Liquidia Corporation (LQDA) Business Model
About Liquidia Corporation
What They Do
Develops therapies for rare cardiopulmonary diseases.
Business Model
The company generates revenue by developing, manufacturing, and commercializing specialized therapies for pulmonary hypertension. Its key product, Yutrepia, is marketed to healthcare providers for outpatient management of pulmonary arterial hypertension and related conditions. Liquidia also engages in collaborations to expand its portfolio of treprostinil-based therapies and explores various formulations to meet diverse patient needs.
Additional Information
Founded in 2004 and based in Morrisville, North Carolina, Liquidia Corporation focuses on innovative drug delivery solutions within the niche market of cardiopulmonary diseases, targeting pulmonologists and specialty clinics. The company aims to address unmet medical needs and establish a strong presence in the U.S. pharmaceuticals and biotech sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
170
CEO
Dr. Roger A. Jeffs Ph.D.
Country
United States
IPO Year
2018
Website
www.liquidia.comLiquidia Corporation (LQDA) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Best Momentum Stocks to Buy for March 10th
STRL, LQDA and NWPX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 10th, 2026.
Mar 10, 2026
By Zacks Equity Research
Zacks #1 Rank Additions
Latest News
Best Momentum Stocks to Buy for March 10th
3 days ago
Quick Summary
STRL, LQDA, and NWPX are ranked as Zacks Rank #1 (Strong Buy) momentum stocks as of March 10, 2026.
Why It Matters
Zacks Rank #1 indicates strong potential for stock price appreciation, signaling favorable momentum for STRL, LQDA, and NWPX, which may attract bullish investor interest.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Liquidia Corp (NASDAQ: LQDA) announced mixed fourth-quarter results on Thursday.
Why It Matters
Mixed results may signal volatility in Liquidia Corp's stock, affecting investor confidence and potential future earnings. Price movements could reflect market reactions to these results.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
Liquidia Corporation (LQDA) held its Q4 2025 earnings call, discussing financial performance and future outlook. Further details on earnings and projections were provided.
Why It Matters
Liquidia Corporation's Q4 2025 earnings call provides insights into financial performance, growth strategies, and market positioning, influencing investment decisions and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Liquidia Corporation (NASDAQ: LQDA) reported its 2025 financial results on March 5, 2026, and will host a webcast at 8:30 a.m. ET to discuss these results and provide a corporate update.
Why It Matters
Liquidia Corporation's financial results could influence stock performance, indicating the company's growth potential and strategic direction in the biopharmaceutical sector, impacting investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Liquidia Corporation (LQDA) reported quarterly earnings of $0.15 per share, surpassing the Zacks Consensus Estimate of $0.08, compared to a loss of $0.46 per share from the previous year.
Why It Matters
Liquidia Corporation's earnings beat expectations and show significant improvement from last year's loss, indicating stronger financial health and potential for future growth, positively influencing investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Positive
Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing
9 days ago
Quick Summary
A fund sold 180,000 shares of Liquidia for ~$5.12 million. Post-sale, it holds 2.435 million shares valued at $84.98 million, representing 11.21% of AUM, outside the top five holdings.
Why It Matters
The sale of Liquidia shares indicates a strategic portfolio adjustment, potentially signaling a shift in confidence or focus away from this stock, influencing market perceptions and valuations.
Source: The Motley Fool
Market Sentiment:
Negative
Frequently Asked Questions About LQDA Stock
What is Liquidia Corporation's (LQDA) stock forecast for 2026?
Based on our analysis of 15 Wall Street analysts, Liquidia Corporation (LQDA) has a median price target of $54.00. The highest price target is $67.00 and the lowest is $19.00.
Is LQDA stock a good investment in 2026?
According to current analyst ratings, LQDA has 8 Buy ratings, 0 Hold ratings, and 1 Sell ratings. The stock is currently trading at $37.58. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LQDA stock?
Wall Street analysts predict LQDA stock could reach $54.00 in the next 12 months. This represents a 43.7% increase from the current price of $37.58. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Liquidia Corporation's business model?
The company generates revenue by developing, manufacturing, and commercializing specialized therapies for pulmonary hypertension. Its key product, Yutrepia, is marketed to healthcare providers for outpatient management of pulmonary arterial hypertension and related conditions. Liquidia also engages in collaborations to expand its portfolio of treprostinil-based therapies and explores various formulations to meet diverse patient needs.
What is the highest forecasted price for LQDA Liquidia Corporation?
The highest price target for LQDA is $67.00 from at , which represents a 78.3% increase from the current price of $37.58.
What is the lowest forecasted price for LQDA Liquidia Corporation?
The lowest price target for LQDA is $19.00 from Serge Belanger at Needham, which represents a -49.4% decrease from the current price of $37.58.
What is the overall LQDA consensus from analysts for Liquidia Corporation?
The overall analyst consensus for LQDA is bullish. Out of 15 Wall Street analysts, 8 rate it as Buy, 0 as Hold, and 1 as Sell, with a median price target of $54.00.
How accurate are LQDA stock price projections?
Stock price projections, including those for Liquidia Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 13, 2026 1:12 PM UTC